Lys-MDA

Lys-MDA, or lysine-MDA, also known as N-(L-lysinamidyl)-MDA, is an entactogen of the phenethylamine, amphetamine, and MDxx families with entactogenic effects, which acts as a prodrug for MDA with a somewhat slower onset of effects and longer duration of action.^[1] Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment-resistant depression and post-traumatic stress disorder. New MDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland.^[2][3][4][5] A phase 1 clinical trial comparing MDMA, MDA, Lys-MDMA, and Lys-MDA has been completed as of August 2024.^[6] The trial results, which included pharmacodynamic and pharmacokinetic findings, was published in September 2025.^[1]

Other namesN-(L-Lysinamidyl)-MDA; N-(L-Lysinamidyl)-3,4-methylenedioxyamphetamine

Routes of
administrationOral^[1]

Drug classSerotonin–norepinephrine–dopamine releasing agent; Serotonin 5-HT₂ receptor agonist; Entactogen; Empathogen; Serotonergic psychedelic; Hallucinogen; Stimulant

ATC code

• None

Quick facts Clinical data, Other names ...

Lys-MDA

Clinical data
Other names	N-(L-Lysinamidyl)-MDA; N-(L-Lysinamidyl)-3,4-methylenedioxyamphetamine
Routes of administration	Oral[1]
Drug class	Serotonin–norepinephrine–dopamine releasing agent; Serotonin 5-HT2 receptor agonist; Entactogen; Empathogen; Serotonergic psychedelic; Hallucinogen; Stimulant
ATC code	None
Pharmacokinetic data
Metabolites	MDA[1]
Identifiers
IUPAC name (2S)-2,6-diamino-N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]hexanamide
CAS Number	1391487-26-5
ChemSpider	130299709
Chemical and physical data
Formula	C16H25N3O3
Molar mass	307.394 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(Cc2ccc1OCOc1c2)NC(=O)C(N)CCCCN
InChI InChI=1S/C16H25N3O3/c1-11(19-16(20)13(18)4-2-3-7-17)8-12-5-6-14-15(9-12)22-10-21-14/h5-6,9,11,13H,2-4,7-8,10,17-18H2,1H3,(H,19,20)/t11?,13-/m0/s1 Key:ZUWUZALZPUJLCD-YUZLPWPTSA-N

Close